Galectin Therapeutics(US:GALT) Globenewswire·2026-02-26 21:05Core Insights - Galectin Therapeutics Inc. is hosting a virtual key opinion leader (KOL) event on March 10, 2026, to discuss the treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension [1][2] - The event will present updated results from the NAVIGATE Phase 3 clinical trial of belapectin, which shows potential as the first treatment for MASH cirrhosis, addressing a significant unmet medical need [2] Company Overview - Galectin Therapeutics focuses on developing therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3, a protein involved in MASH and fibrosis [7] - Belapectin has received Fast Track designation from the U.S. FDA and is positioned to address the pressing medical need for treatments in liver cirrhosis [7] Clinical Development - The NAVIGATE Phase 3 trial results reinforce the antifibrotic and disease-modifying potential of belapectin, which may be the first approved therapy for preventing or treating varices in MASH cirrhosis [2] - The company aims to leverage its scientific expertise and external relationships to achieve efficient drug development [7]